Brainsway (BWAY) Stock Price, News & Analysis

Company Overview

BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.

The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines. BrainsWay also develops additional clinical applications for its technology, including potential treatments for other psychiatric and neurological conditions.

Founded in 2003, BrainsWay serves hospitals, clinics and other healthcare providers in the United States and international markets. The company is headquartered in Burlington, Massachusetts, and has roots in Israel, where its technology was developed. Its shares trade on the Nasdaq under the symbol BWAY.

Key Stats

• Today's Range: $11.70 to $11.70
• 50-Day Range: $11.46 to $16.60
• 52-Week Range: $7.14 to $17.40
• Volume: 4,344 shs
• Average Volume: 151,102 shs
• Market Capitalization: $463.84 million
• P/E Ratio: 25.96
• Dividend Yield: N/A
• Price Target: $18.20
• Consensus Rating: Moderate Buy

Brainsway Stock Analysis - MarketRank™

Brainsway scored higher than 91% of companies evaluated by MarketBeat, and ranked 32nd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Brainsway has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Brainsway has a consensus price target of $18.20, representing about 58.1% upside from its current price of $11.51.

Amount of Analyst Coverage

Brainsway has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 72.73%

Earnings Growth

Earnings for Brainsway are expected to grow by 72.73% in the coming year, from $0.33 to $0.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainsway is 26.16, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainsway is 26.16, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 223.62.

Price to Book Value per Share Ratio

Brainsway has a P/B Ratio of 6.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.77% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 2.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently increased by 25.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainsway does not currently pay a dividend.

Dividend Growth

Brainsway does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.18

News Sentiment

Brainsway has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Brainsway this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for BWAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Brainsway to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainsway insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

30.11% of the stock of Brainsway is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BWAY
• CIK: 1505065
• Web: www.brainsway.com
• Phone: (722) 582-4030
• Fax: N/A
• Employees: 129
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Brainsway: $18.20
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +58.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.44
• Trailing P/E Ratio: 26.16
• Forward P/E Ratio: 34.88
• P/E Growth: N/A
• Net Income: $7.57 million
• Net Margins: 15.65%
• Pretax Margin: 15.94%
• Return on Equity: 12.74%
• Return on Assets: 8.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.27

Sales & Book Value

• Annual Sales: $60.70 million
• Price / Sales: 7.63
• Cash Flow: $0.23 per share
• Price / Cash Flow: 50.91
• Book Value: $1.87 per share
• Price / Book: 6.16

Miscellaneous

• Outstanding Shares: 40,253,000
• Free Float: 32,605,000
• Market Cap: $463.31 million
• Optionable: Not Optionable
• Beta: 1.29